1. Volume 14, Issue 6, Pages 481-489 (May 2013)
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open- label phase 3 trial 
Tom Waddell, MBBCh, Ian Chau, MD, Prof David Cunningham, MD, David Gonzalez, PhD, Alicia Frances Clare Okines, MBBCh, Andrew Wotherspoon, MBBCh, Claire Saffery, Gary Middleton, MD, Jonathan Wadsley, MBBCh, Prof David Ferry, PhD, Wasat Mansoor, PhD, Tom Crosby, MBBS, Fareeda Coxon, MBBS, David Smith, MD, Justin Waters, PhD, Timothy Iveson, MD, Stephen Falk, MD, Sarah Slater, MD, Clare Peckitt, MSc, Yolanda Barbachano, PhD 
The Lancet Oncology 
Volume 14, Issue 6, Pages (May 2013)
DOI: /S (13)
Copyright © 2013 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
EOC=epirubicin, oxaliplatin, and capecitabine. mEOC+P=modified EOC plus panitumumab.
The Lancet Oncology  , DOI: ( /S (13) )
Copyright © 2013 Elsevier Ltd Terms and Conditions

3. Figure 2
Overall survival in 553 patients in the intention-to-treat population, by treatment group
Patients still on treatment at the time of trial closure and treatment crossover were censored. EOC=epirubicin, oxaliplatin, and capecitabine. mEOC+P=modified EOC plus panitumumab.
The Lancet Oncology  , DOI: ( /S (13) )
Copyright © 2013 Elsevier Ltd Terms and Conditions

4. Figure 3
Forest plot of hazard ratios (HR) for overall survival according to baseline characteristics
EOC=epirubicin, oxaliplatin, and capecitabine. mEOC+P=modified EOC plus panitumumab.
The Lancet Oncology  , DOI: ( /S (13) )
Copyright © 2013 Elsevier Ltd Terms and Conditions

5. Figure 4
Progression-free survival in 553 patients in the intention-to-treat population, by treatment group
Patients still on treatment at the time of trial closure and treatment crossover were censored. EOC=epirubicin, oxaliplatin, and capecitabine. mEOC+P=modified EOC plus panitumumab.
The Lancet Oncology  , DOI: ( /S (13) )
Copyright © 2013 Elsevier Ltd Terms and Conditions

6. Figure 5
Overall and progression-free survival in 276 assessable patients in the mEOC+P group, by skin rash grade (grade 0 vs grade 1–4)
mEOC+P=modified epirubicin, oxaliplatin, and capecitabine plus panitumumab.
The Lancet Oncology  , DOI: ( /S (13) )
Copyright © 2013 Elsevier Ltd Terms and Conditions